ATHE alteritytherapeutics.com: Forward Price-to-Revenue Multiple
Alterity Therapeutics (ATHE) has established a robust global distribution system for neuropreparations that minimizes supply chain disruptions. These logistical achievements correlate with the development of Parkinson's disease medications, supporting the forward P/S projections where the value is maintained at 2.20. However, the long-term sustainability of the business and its patent protection will only be fully realized upon the completion of final clinical trials.
ATHE (Alterity Therapeutics Ltd.): analytical breakdowns and indicator data
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Alterity Therapeutics|ATHE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Alterity Therapeutics|ATHE - Aggregate Debt Obligations|Debts to Book Capitalization Alterity Therapeutics|ATHE - Company Long-Term Debts|Company Short-Term Debt Alterity Therapeutics|Quick Ratio alteritytherapeutics.com
- net income and valuation multiples indicators:
ATHE - Company Net Income|Future Profit Alterity Therapeutics|ATHE - P/E Multiple|Projected Price to Earnings Alterity Therapeutics Limited|ATHE - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Alterity Therapeutics Ltd|ATHE - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Alterity Therapeutics|ATHE - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months alteritytherapeutics.com|ATHE - Expected net earnings per share growth this year|Earnings growth forecast for next year Alterity Therapeutics
- issuer revenue and sales details:
Summary company analysis:Alterity Therapeutics ATHE
Forward P/S relates market capitalization to projected revenue, allowing for an assessment of the premium paid for future cash flows and the risks of correction should expectations be revised. By analyzing the current forward P/S level, an investor determines the capital margin of safety for Alterity Therapeutics (ATHE), whose valuation relies on the commercialization potential of unique drugs for the therapy of neurodegenerative pathologies and Parkinson's disease.
Competitors of Alterity Therapeutics
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|clene.com (CLNN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PEPG (PepGen Inc)|Forward P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Projected Revenue|Grace Tx - Forward P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
